India — July-September 2025 — The VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty^®), independently developed by MicroPort CardioFlow Medtech Corporation (CardioFlow, 02160.HK), has successfully completed its first 22 commercial implants in India, marking a significant advancement in accessible, innovative structural hearttherapies for local patients.

The milestone procedures were led by an expert team of physicians from premier institutions of India, including Christian Medical College (Vellore), Narayana Institute of Cardiac Sciences (Bangalore), PGIMER (Chandigarh), Medanta Group of Hospitals (Gurugram), Sir J J Group of Hospitals (Mumbai), Criticare Asia Medico Hospital (Mumbai), Max Hospital (Delhi), Kovai Medical Centre (Coimbatore), Sri Kauvery Medical Centre (Chennai), Magnum Heart Institute (Nashik), Apex Heart Institute (Ahmedabad).

With Lead Proctors Dr. Ole De Backer (Denmark), Dr. Amat Santos (Spain), Dr. J Kim (Korea), Dr. B H Hwang (Korea), Dr. Anuruck Jeamanukoolkit (Thailand) providing expert guidance, the cases demonstrated the system's exceptional clinical performance—including rapid postoperative recovery through minimally invasive approaches and successful management of complex anatomies—validating its precision and adaptability.

As the world's first electrically retrievable TAVI system approved for market launch, VitaFlow Liberty^® obtained EU CE MDR certification in 2024, making it the first China-developed TAVI system to achieve this milestone, and promptly initiated clinical applications across multiple European countries. Since May 2025, its commercialization process has accelerated significantly, marked by its successful entry into seven new country markets within just two months and rapid adoption in numerous key hospitals. To date, the VitaFlow^® series of TAVI products have been introduced into over 20 countries and regions worldwide, covering more than 800 core hospitals, and have treated over 10,000 patients with aortic valve disease.

The successful completion of the first commercial implants in India, the world's most populous country, not only exemplifies successful collaboration between top-tier heart centers in Europe and Asia and the sharing of medical technology within Asia, but also reflects the innovative integration of "Intelligently manufactured in China" products into international healthcare systems. Furthermore, this milestone will assist the company in further expanding into Asian and global markets, thereby continuously enhancing its profitability. It will also help promote high-quality, accessible advanced medical solutions for a greater number of patients, injecting innovative momentum into the global field of structural heart disease intervention.

São Paulo, Brazil — On July 17–31, 2025, the VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (referred to as "VitaFlow Liberty^®"), independently developed by MicroPort CardioFlow Medtech Corporation (02160.HK), successfully completed Brazil’s first 7 commercial clinical cases at Santa Casa de São Paulo.

As one of Brazil’s oldest charitable hospitals, Santa Casa de São Paulo has long been renowned for its excellence in medical care and academic influence. All seven procedures were performed under the guidance of renowned Argentine cardiovascular interventional expert Prof. Matías Sztefman, with Prof. José Mariani, Prof. Eduardo Pessoa, Prof. Edgar Quintella, Prof. Guy Prado, Prof. Pedro Lemos, and Prof. Ricardo Ghetti leading the operations. Postoperative evaluations confirmed no significant paravalvular leakage or complications, with all cases achieving complete success.

The surgical team expressed high satisfaction with the clinical performance of VitaFlow Liberty^®. Multiple operators noted: "The hybrid-density design of this valve stent provides sufficient radial force, offering a distinct advantage in TAVI procedures for highly calcified aortic valve lesions. Additionally, the electric retrievable system is highly user-friendly, enabling precise and stable valve deployment. We look forward to bringing this product to more Brazilian patients."

The successful completion of Brazil’s first 7 commercial cases within just two months of VitaFlow Liberty^®’s launch—marking its entry into Latin America’s largest healthcare market—not only validates the product’s clinical strengths but also injects strong momentum into CardioFlow’s global strategy. Moving forward, the company will deepen innovation, accelerate expansion into high-potential, high-growth overseas markets, and empower broader patient populations worldwide with China-developed premium medical devices, contributing more "Chinese solutions" to global healthcare.

Shanghai, China — MicroPort CardioFlow MedTech Corporation (CardioFlow, 02160.HK) recently announced that its self-developed second-generation balloon catheter, the Alwide^® Plus Balloon Catheter (Alwide^® Plus), has successfully obtained EU CE Mark certification (Certificate No.: 6126688CE01, 6126688TD02). This milestone makes Alwide^® Plus the company's fourth independently developed product approved for the European market, following the VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty^®) and the AnchorMan^® Left Atrial Appendage Closure System along with its access system.

As a critical supporting device for TAVI (Transcatheter Aortic Valve Implantation), Alwide^® Plus received marketing approval from China's National Medical Products Administration (NMPA) in July 2021 (Registration No.: 20213030586) and has since been introduced in over ten countries and regions, including Argentina, Colombia, Brazil, Thailand, Russia, Indonesia, Saudi Arabia, Hong Kong (China), Mexico, Kazakhstan, Belarus, and Ecuador.

Since its launch, Alwide^® Plus has gained widespread recognition among physicians in more than 700 leading hospitals worldwide due to its outstanding clinical performance. Its ultra-low compliance enables precise balloon dilation, minimizing vascular injury, while its high burst pressure capability effectively dilates severely calcified areas, addressing patients' challenging calcification profiles. The catheter's rapid inflation and deflation properties significantly reduce prolonged blood flow obstruction, shortening pacing time and lowering procedural risks. Additionally, its enhanced puncture resistance improves both user experience and intraoperative safety during balloon dilation.

The CE Mark approval of Alwide^® Plus will not only provide European TAVI procedures with optimized treatment options and contribute to the company's overseas revenue growth but also accelerate the commercialization of VitaFlow Liberty^® in Europe while expediting the regulatory processes for both products in other global markets. This achievement further advances CardioFlow's internationalization strategy and underscores its leading technological capabilities, R&D strength, and forward-thinking approach in the global structural heart disease medical device sector.

Moving forward, CardioFlow's four CE-certified products will synergistically enhance one another's commercialization, strengthening the company's competitive edge in the high-end global medical device market and delivering superior medical solutions to patients with structural heart disease worldwide.